Mazyar Shadman

@mshadman

Assistant Professor U of Washington, Fred Hutchinson. Lymphoma/CLL oncologist. Tweets are mine.

Vrijeme pridruživanja: ožujak 2009.

Tweetovi

Blokirali ste korisnika/cu @mshadman

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mshadman

  1. proslijedio/la je Tweet
    23. sij

    Blown away as I watch a nearby community healthcare system implode due to management recommendations made by "consultants." Highly paid and highly powerful individuals who know nothing about patient care - driving up costs and breaking what they are paid to fix.

    Poništi
  2. 8. sij
    Poništi
  3. 26. pro 2019.

    Very interested in knowing 's opinion about intermittent fasting.

    Poništi
  4. proslijedio/la je Tweet

    Thrilled to see When Blood Breaks Down in the spring catalogue, now on-line! thank you for your support and the lovely sentiments! 😊😊😊

    Poništi
  5. proslijedio/la je Tweet
    21. pro 2019.

    Very important study confirming what many of us have suspected for years - that antioxidant supplements impair chemotherapy efficacy

    Poništi
  6. proslijedio/la je Tweet

    This is the paper I’m most proud of having written in 2019. We can learn a lot from Bob.

    Poništi
  7. 20. pro 2019.

    Seattle's rainiest day in the past decade!

    Poništi
  8. 18. pro 2019.
    Poništi
  9. 17. pro 2019.
    Poništi
  10. 17. pro 2019.

    Great essay by Dr. Kalaycio . I was lucky to work with him when I was a resident on the leukemia service at the (and Dr. Hamilton was our fellow!)

    Poništi
  11. proslijedio/la je Tweet

    Clonal hematopoiesis is a major source of somatic mutations detected in liquid biopsies of patients | |

    Poništi
  12. proslijedio/la je Tweet
    16. pro 2019.

    Antigen loss and tumor phenotype heterogeneity are significant obstacles to the success of therapy. Balakrishnan A from Stan Riddell's lab explored Designed Ankyrin Repeat Proteins (DARPins) instead of scFv for multiantigen targeting

    Poništi
  13. 16. pro 2019.
    Poništi
  14. 16. pro 2019.

    Very interested in knowing how other centers approach this situation

    Prikaži ovu nit
    Poništi
  15. 16. pro 2019.

    DLBCL s/p CART in CR (day90). fit with a donor. Not many options if relapses. alloSCT vs. observation?

    Prikaži ovu nit
    Poništi
  16. 16. pro 2019.

    Press release only: not superior to in . Better tox profile as expected. trial has finished enrollment.

    Poništi
  17. 15. pro 2019.

    Excellent by Dr. Fonseca ( ) on t(11;14) was solicited by for publication. Beginning of a new era?

    Poništi
  18. proslijedio/la je Tweet
    15. pro 2019.

    We have to make it crystal clear: every cancer patient in the world is a human being like ourselves and deserves optimal therapy based on current evidence. Every patient.

    Poništi
  19. proslijedio/la je Tweet
    14. pro 2019.

    WHAT IS THE RISK CLASSIFICATION OF THE t(11;14) in MM? This has been a long-debated question and probably asked in the wrong way. I have always had a special interest in the t(11;14) and want to tell a story and how it relates to venetoclax. 1/x

    Prikaži ovu nit
    Poništi
  20. 13. pro 2019.

    Glad this is a priority topic for . Working on a project to show different outcomes in high-risk CLL pts in different countries in the novel agents era.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·